EUVIMEDEUVIMED entdecken
Crossref

Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database

Min Wang, Zhiyun Yang, Min Yan, Shao Liu, Sa Xiao

Journal of Affective Disorders · 2025-11 · 389 · 119670

DOI: 10.1016/j.jad.2025.119670 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2025-11. Verfasst von Min Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; National Clinical Research Center for Geriatric Di…. Hauptthemen laut MEDLINE: Liraglutide, Glucagon-Like Peptides, Suicide, Self-Injurious Behavior. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Xiangya Hospital Central South University, Natural Science Foundation of Hunan Province, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Post-marketing surveillance has indicated potential suicide and self-injury signals in patients taking GLP-1RAs for weight management, despite no current psychiatric warnings in labeling. This study evaluated the association between GLP-1RAs and depression/suicide events using FDA Adverse Event Reporting System (FAERS) data. METHODS: A retrospective pharmacovigilance study analyzed FAERS data (2004-2024) using reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) analyses to evaluate depression and suicide/self-injury adverse events for liraglutide, semaglutide, and tirzepatide. RESULTS: Analysis included 8284 reports for liraglutide (n = 3022), 14,435 for semaglutide (n = 4233), and 15,597 for tirzepatide (n = 5722). Significant signals were identified only for semaglutide in both depression (ROR, 1.87; 95 % CI, 1.60-2.20) and suicide/self-injury events (ROR, 1.73; 95 % CI, 1.46-2.04). Effects were consistent across sex groups but most pronounced in ages 18-64. Post-weight management approval saw increased reporting, particularly in European and North American regions. Tirzepatide showed significantly lower mortality rates (0.26 %) compared to other agents. CONCLUSION: Findings identified significant depression and suicidality signals with semaglutide in weight management. For patients requiring weight reduction therapy, particularly those with psychiatric comorbidities, tirzepatide may represent a more appropriate choice based on its superior safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideGlucagon-Like PeptidesSuicideSelf-Injurious BehaviorDepressionAnti-Obesity AgentsHumansMaleFemaleAdultMiddle AgedRetrospective StudiesAdverse Drug Reaction Reporting SystemsUnited StatesPharmacovigilanceAdolescentYoung AdultAgedDatabases, FactualUnited States Food and Drug AdministrationTirzepatideGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

DepressionFAERS databaseGLP-1RAsObesityPharmacovigilanceSuicide/self-injury

Substanzen

LiraglutideGlucagon-Like PeptidesAnti-Obesity AgentsTirzepatideGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008,…
  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
  • Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan 528200, Guangdong, China. Electronic address: xiaosa_sophia@163.com.

Förderung

  • Xiangya Hospital Central South University
  • Natural Science Foundation of Hunan Province
  • The Sixth Affiliated Hospital, School of Medicine, South China University of Technology

Zitieren

APA

Wang, M., Yang, Z., Yan, M., Liu, S., & Xiao, S. (2025). Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database. Journal of Affective Disorders, 389, 119670. https://doi.org/10.1016/j.jad.2025.119670

Vancouver

Wang M, Yang Z, Yan M, Liu S, Xiao S. Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database. Journal of Affective Disorders. 2025;389:119670. doi:10.1016/j.jad.2025.119670

BibTeX
@article{Wang2025,
  author = {Wang, Min and Yang, Zhiyun and Yan, Min and Liu, Shao and Xiao, Sa},
  title = {Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database},
  journal = {Journal of Affective Disorders},
  year = {2025},
  volume = {389},
  pages = {119670},
  doi = {10.1016/j.jad.2025.119670}
}
Kostenlos starten →